Trial Profile
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 25 May 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Aug 2018 Planned initiation date changed from 14 Jul 2018 to 30 Nov 2018.
- 17 Jul 2018 Planned initiation date changed from 15 Jul 2018 to 14 Jul 2018.